Indications
Vericiguat is used to lower the risk of cardiovascular death and of being admitted to hospital for heart failure (HF). It is meant for adults who have symptomatic chronic HF with an ejection fraction of less than 45%, and who have recently been in hospital for heart failure or needed IV diuretics as an outpatient.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme makes cyclic guanosine monophosphate (cGMP) inside the cell. This cGMP acts as a second messenger and helps regulate vascular tone, cardiac contractility and cardiac remodeling. In heart failure, the body makes less NO and sGC is less active, and this may add to the dysfunction of the heart muscle and blood vessels. Vericiguat stimulates sGC directly, both independently of NO and together with NO, so the level of cGMP inside the cell rises. The result is relaxation of smooth muscle and widening of the blood vessels (vasodilation).
Pregnancy & Breastfeeding
Pregnancy: Vericiguat must not be used in pregnancy, because it may cause fetal harm. Pregnancy should be ruled out before treatment starts. Women who could become pregnant must use effective contraception during treatment and for one month after stopping it.
Nursing mothers: There are no data on whether Vericiguat passes into human milk, what effect it has on a breastfed infant, or whether it changes milk production. Because breastfed infants could have serious adverse reactions to Vericiguat, women should be advised not to breastfeed while they are taking it.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.